Compass Therapeutics, Inc. (NasdaqCM: CMPX)
Health Care · Biotechnology · US
$0.94
-5.59% today · -76.8% 1Y
Compass Therapeutics, Inc. (NasdaqCM: CMPX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $178.83M and employs 39 people.
Over the last twelve months the share price has lost 76.8%, trading between 0.83 and 6.88.
Tweenvest scores Compass Therapeutics, Inc. across four factors: quality 39/100, value 27/100. Its strongest factor is quality.
CMPX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $178.83M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.40
- Dividend yield
- —
- Beta (5Y)
- 0.91
- 52-week high
- $6.88
- 52-week low
- $0.83
- Avg volume (3M)
- —
- Shares outstanding
- 180.09M
- Employees
- 39
- Next earnings
- —
About Compass Therapeutics, Inc.
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L1. The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.
- ISIN
- US20454B1044
- Founded
- 2014
- Listed since
- Apr 5, 2021
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| IntoCell, Inc.KOSDAQ: A287840 | $193.53M | ₩17,320.00 | -4.04% |
| Adagene Inc.NasdaqGM: ADAG | $185.32M | $2.74 | -0.72% |
| Precision BioSciences, Inc.NasdaqCM: DTIL | $180.24M | $6.53 | -2.83% |
| Hester Biosciences LimitedBSE: 524669 | $179.48M | Rs2,041.90 | -4.61% |
| Cue Biopharma, Inc.NasdaqCM: CUE | $178.78M | $24.61 | -11.03% |
| Uwell Biopharma, Inc.TPEX: 7902 | $175.67M | NT$28.00 | -4.92% |
| ALX Oncology Holdings Inc.NasdaqGS: ALXO | $174.23M | $1.26 | +0.80% |
| GC Genome CorporationKOSDAQ: A340450 | $173.64M | ₩9,870.00 | +11.15% |
Figures last refreshed Oct 11, 2026.